Rennova Health, Inc. · OTC:RNVA

Rennova Health — CollabRx — IPO Roadshow (February 2015)

27 slides from Rennova Health's IPO roadshow presentation, Feb 17, 2015

Slide 1: CollabRx: Empowering Cancer Care
NASDAQ: CLRX CollabRx: Empowering Cancer Care Expert systems for genomics-based cancer treatment planning Issuer Free Writing ProspectusFiled Pursuant to Rule 433Registration No. 333-199477February 17, 2015
Slide 2: Safe Harbor
2 Safe Harbor When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Importan
Slide 3: Free Writing Prospectus Statement
3 Free Writing Prospectus Statement CollabRx, Inc. has filed a registration statement on Form S-1 (Registration No. 333-199477) with the Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. A copy of the preliminary prospectus describing the terms of t
Slide 4: Business Update
Business Update Key Reasons for current offering of shares:To cure NASDAQ Net Equity Deficiency before hearing on 2/19/15To provide capital for continued operation of CollabRxProposed business combination with Medytox Solutions, Inc.Signed non-binding LOI on 12/6/14 for potential business combinatio
Slide 5: Proposed Deal Terms
Proposed Deal Terms Reverse merger transactionCollabRx will be surviving legal parentMedytox will be surviving accounting parentAll Medytox shares to be cancelled at closing and exchanged for CLRX common, except for Series B Preferred stock which will be exchanged for $25M of Convertible Promissory
Slide 6: Medytox Solutions, Inc.
Medytox Solutions, Inc. Vertically integrated provider of clinical lab testing and related servicesCurrently serves drug rehab, pain management, private physicians / clinics Employs cutting-edge technology, systems and services to improve efficiency and reduce cost of patient careStrong record of or
Slide 7: Stage of Negotiations
Stage of Negotiations The Letter of Intent that was entered into by CollabRx and Medytox on December 6, 2014 is non-binding. We have not yet signed a definitive merger agreement. We have not sought approval from our Board of Directors for the proposed business combination and will not do so until we
Slide 8: Overview of CollabRx
Overview of CollabRx A clinical decision-support company for precision oncologyWe translate expert knowledge about complex molecular medicine and make it relevant, accessible and actionable for practicing physiciansNot a lab – we focus on data interpretation, reporting and downstream analytics for c
Slide 10: Oncologists are our market
Oncologists are our market Automated, SaaS reporting service for complex NGS panelsExpert-vetted Actionability FrameworkXML data or physician-ready reportsVolume-based subscription / per test fee GVA™ Service “Expert systems” for treatment planning (Therapy Finders™)Relevant medical news as it break
Slide 11: Newly emerging market for genomic-based testing in cancer
11 Newly emerging market for genomic-based testing in cancer Addressable US market ~ 13 million patients7 million (55%) with a strong genetic association*1.7 million new US patients in 2013 and 14 million globally*Growing to almost 3 million new US patients each year by 2050**Each day approximately
Slide 12: Need to address rapidly changing science and standards in oncology
Need to address rapidly changing science and standards in oncology “Our patients rely on us to guide them in this new landscape of molecular oncology. But the field is just changing too quickly. We simply do not have enough hours in the day to see patients and stay abreast of the field.” Source: Com
Slide 13: GVA focused on knowledge-based portions of the clinical genetic testing workflow
GVA focused on knowledge-based portions of the clinical genetic testing workflow Data Analysis/InterpretationClinical decision support layerResults in XML file ReportingVisual analysis, configure report parametersResults in physician ready report (e.g., PDF file) CollabRx Specimen HandlingAcquisitio
Slide 14: Therapy Finders make expert knowledge available at the office and at home
Therapy Finders™ make expert knowledge available at the office and at home Current Therapy Finders for Lung, Colorectal, and Metastatic Breast cancers and Melanoma Recently launched CancerRx mobile app includes Therapy Finders and MedPage Today newsfeed 14 © Copyright 2015 CollabRx, Inc. - All Right
Slide 15: Knowledge Base of Treatment Models
15 Editorial Boards& Guidelines Knowledge Base of Treatment Models In-House KnowledgeExperts Combine in-house and external experts to create a unique knowledge resource Representative Sources of Guidelines Representative Available Data Sources: © Copyright 2015 CollabRx, Inc. - All Rights Reserved N
Slide 16: Over 75 expert advisors provide best practice insights
Melanoma Melanoma Lung Breast Breast Colorectal Sarcoma Leukemia Prostate Pancreas Pan Cancer Breast Over 75 expert advisors from leading institutions provide best practice insights Representative institutional affiliations of advisors: An unprecedented network of uncompensated volunteers to advance
Slide 17: Minutes Not Days: GVA System
Minutes Not Days GVA System: Automated, scalable, contextualized assembly of content for labs entering the genomic testing market in cancer Platform for interpretation and reporting Testing and QA Project management Support Build/ deploy policies Content updates Hosting Availability Documentation Ap
Slide 18: Competitive Strengths
Competitive Strengths Proprietary knowledgebase is focused on actionable information for physiciansFocus is on providing actionable information that physicians can use to plan treatment strategies for their advanced cancer patients and identifying the evidence in the public domain that justifies the
Slide 19: Multiple current and potential revenue sources
Multiple current and potential revenue sources Web and Mobile Apps Pharma Physicians and patients Pharma MedPage Today Per-test-fees(Software-as-a-Service) Volume-based Subscriptions Ad revenue / Sponsorships Customization(Fee for service) “Freemium” / PremiumSubscriptions Data analyticsLicense Fees
Slide 20: Long-term product strategy
Long-term product strategy Business Model Customer Base Diagnostic Content Provider Outcomes Driver Early Adopter Oncologists & Pathologists Broader Provider User Base Payers / Pharma Content supplier for platform providers and related customers Initial penetration of diagnostic labsOnline media pre
Slide 21: Partnerships, strategic alliances, customers and sponsors
Partnerships, strategic alliances, customers and sponsors 21 Academic InstitutionsCancer CentersProfessional OrganizationsUniversity of ChicagoOhio State UniversityJackson LaboratoryOncoSolutions Cancer Center (Singapore)American Society of Clinical Oncology (ASCO)College of American Pathologists (C
Slide 22: Seasoned leadership team
22 Seasoned leadership team Thomas Mika, MBA; Chairman, President, and CEO – Tegal, IMTEC, Cresap, National Science Foundation, HBS George Lundberg, MD; Chief Medical Officer and Editor-in-Chief – AMA, WebMD, Medscape, Stanford (Professor, pathology), Lundberg InstituteClifford Baron, PhD; Vice Pres
Slide 23: Board of Directors
23 Board of Directors Thomas R. Mika, Chairman (see Management Team)Paul R. Billings, MD, PhD – Author, lecturer, consultant, professor and thought leader in genomic medicine. CMO, Thermo Fisher Scientific, Member of FDA Science Board, VA Genomic Medicine Advisory Committee, IOM Genomic Medicine Rou
Slide 24: CollabRx, Inc. Balance Sheet
CollabRx, Inc. Balance Sheet6/30/14 © Copyright 2014 CollabRx, Inc. - All Rights Reserved NASDAQ CM: CLRX © Copyright 2015 CollabRx, Inc. - All Rights Reserved NASDAQ CM: CLRX 24
Slide 26: Investment Thesis
Investment Thesis Highly regarded, industry-leading position with unique, proprietary platform to address critical need of interpretation and reporting on genomic test results to physicians at scaleDeveloped and published objective criteria for “Actionability” of genomic test results with high-profi

CollabRx — IPO Roadshow (February 2015) on 6ix

Rennova Health — CollabRx — IPO Roadshow (February 2015)

Slide 1: CollabRx: Empowering Cancer Care

Slide 2: Safe Harbor

Slide 3: Free Writing Prospectus Statement

Slide 4: Business Update

Slide 5: Proposed Deal Terms

Slide 6: Medytox Solutions, Inc.

Slide 7: Stage of Negotiations

Slide 8: Overview of CollabRx

Slide 9: CollabRx Business Models

Slide 10: Oncologists are our market

Slide 11: Newly emerging market for genomic-based testing in cancer

Slide 12: Need to address rapidly changing science and standards in oncology

Slide 13: GVA focused on knowledge-based portions of the clinical genetic testing workflow

Slide 14: Therapy Finders make expert knowledge available at the office and at home

Slide 15: Knowledge Base of Treatment Models

Slide 16: Over 75 expert advisors provide best practice insights

Slide 17: Minutes Not Days: GVA System

Slide 18: Competitive Strengths

Slide 19: Multiple current and potential revenue sources

Slide 20: Long-term product strategy

Slide 21: Partnerships, strategic alliances, customers and sponsors

Slide 22: Seasoned leadership team

Slide 23: Board of Directors

Slide 24: CollabRx, Inc. Balance Sheet

Slide 25: Capitalization

Slide 26: Investment Thesis

Slide 27: www.collabrx.com